SphK/S1P在心血管疾病中的作用

doi:10.16352/j.issn.1001-6325.2024.08.1175

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (8): 1175-1179.doi: 10.16352/j.issn.1001-6325.2024.08.1175

SphK/S1P在心血管疾病中的作用

唐丽鸿, 陈春玲^*

新疆医科大学第一附属医院麻醉科,新疆乌鲁木齐 830054

收稿日期:2023-12-13 修回日期:2024-05-08 出版日期:2024-08-05 发布日期:2024-07-24
通讯作者: ^*1527693169@qq.com
基金资助:
新疆维吾尔自治区重点实验室开放课题(2022D04020)

Role of SphK/S1P in cardiovascular diseases

TANG Lihong, CHEN Chunling^*

Department of Anesthesiology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China

Received:2023-12-13 Revised:2024-05-08 Online:2024-08-05 Published:2024-07-24
Contact: ^*1527693169@qq.com

摘要/Abstract

摘要： 磷酸鞘氨醇(S1P)是一种活性高的膜磷脂类代谢物,对心血管系统具有重要的生理作用。鞘氨醇激酶(SphK)是一种脂肪酶,对维持体内S1P水平的稳定非常重要。S1P通过催化调节与细胞表面的G蛋白偶联受体(S1PR1-5)的结合,从而在心血管疾病中发挥不同的生理学效应,如参与调控动脉粥样硬化、心肌缺血再灌注损伤、心肌梗死、心力衰竭等疾病的发生发展,维持血管内皮细胞屏障功能,保护内皮糖萼层,白细胞黏附以及炎性反应等生理病理过程。

关键词: 1-磷酸鞘氨醇, 鞘胺醇激酶, 心血管疾病, 内皮糖萼层

Abstract: Sphingosine-1-phosphate (S1P) is a highly active membrane phospholipid metabolite with important physiological roles in the cardiovascular system. Sphingosine kinase (SphK) is a lipase that is important for maintaining stable S1P levels in vivo. S1P exerts different physiological effects in cardiovascular diseases by catalytically regulating the binding of S1P to G protein-coupled receptors (S1PR1-5) on the cell surface, thus exerting different physiological effects in cardiovascular diseases.For example, they are involved in regulating the development of diseases such as atherosclerosis, myocardial ischemia-reperfusion injury, myocardial infarction, heart failure and other diseases, maintaining the barrier function of vascular endothelial cells, protecting the endothelial glycocalyx layer, leukocyte adhesion, inflammatory reactions and other pathophysiologic processes.

Key words: sphingosine-1-phosphate, sphingosine kinase, cardiovascular diseases, endothelial glycocalyx layer

中图分类号:

唐丽鸿, 陈春玲. SphK/S1P在心血管疾病中的作用[J]. 基础医学与临床, 2024, 44(8): 1175-1179.

TANG Lihong, CHEN Chunling. Role of SphK/S1P in cardiovascular diseases[J]. Basic & Clinical Medicine, 2024, 44(8): 1175-1179.

参考文献

[1] Dixit D, Hallisey VM, Zhu EY, et al. S1PR1 inhibition induces proapoptotic signaling in T cells and limits humoral responses within lymph nodes[J]. J Clin Invest, 2024,134:e174984. doi:10.1172/JCI174984.
[2] Zhao T, Ding T, Sun Z, et al. SPHK1/S1P/S1PR pathway promotes the progression of peritoneal fibrosis by mesothelial-mesenchymal transition[J]. FASEB J, 2024,38:e23417. doi:10.1096/fj.202301323R.
[3] Li JJ, Zhao XY, Wang Y, et al. Endothelial KCa3.1 and KCa2.3 mediate S1P(sphingosine-1-phosphate)-depend-ent vasodilation and blood pressure homeostasis[J]. Arterioscler Thromb Vasc Biol, 2023,43:726-738. doi:10.1161/ATVBAHA.122.318820.
[4] Ji X, Chen Z, Wang Q, et al. Sphingolipid metabolism controls mammalian heart regeneration[J]. Cell Metab, 2024,36:839-856.e8.
[5] Karam M, Auclair C. Sphingosine-1-phosphate as lung and cardiac vasculature protecting agent in SARS-CoV-2 infection[J]. Int J Mol Sci, 2023,2413088. doi:10.3390/ijms241713088.
[6] Therond P, Chapman MJ. Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatment[J]. Curr Opin Lipidol, 2022,33:199-207. doi:10.1097/MOL.0000000000000825.
[7] Sawashita Y, Kazuma S, Tokinaga Y, et al. Albumin protects the ultrastructure of the endothelial glycocalyx of coronary arteries in myocardial ischemia-reperfusion injury in vivo[J]. Biochem Biophys Res Commun, 2023,666:29-35. doi:10.1016/j.bbrc.2023.04.110.
[8] Piccoli M, Cirillo F, Ghiroldi A, et al. Sphingolipids and atherosclerosis: the dual role of ceramide and sphingosine-1-phosphate[J]. Antioxidants (Basel), 2023,12:143. doi:10.3390/antiox12010143.
[9] Yu FC, Yuan CX, Tong JY, et al. Protective effect of sphingosine-1-phosphate for chronic intermittent hypoxia-induced endothelial cell injury[J]. Biochem Biophys Res Commun, 2018,498:1016-1021. doi:10.1016/j.bbrc.2018.03.106.
[10] Katunaric B, SenthilKumar G, Schulz ME, et al. S1P(sphingosine-1-phosphate)-induced vasodilation in human resistance arterioles during health and disease[J]. Hypertension, 2022,79:2250-2261. doi:10.1161/HYPERTENSIONAHA.122.19862.
[11] Manzo OL, Nour J, Sasset L, et al. Rewiring endothelial sphingolipid metabolism to favor S1P over ceramide protects from coronary atherosclerosis[J]. Circ Res, 2024,134:990-1005. doi:10.1161/CIRCRESAHA.123.323826.
[12] Liu X, Wu J, Zhu C, et al. Endothelial S1pr1 regulates pressure overload-induced cardiac remodelling through AKT-eNOS pathway[J]. J Cell Mol Med,2020,24:2013-2026. doi:10.1111/jcmm.14900.
[13] 陈铿铨,王忠芹,刘超等.1-磷酸鞘胺醇通过其受体3改善压力超负荷诱导的病理性心肌肥厚[J].中国心血管杂志,2022,27:459-467.
[14] Magaye RR, Savira F, Hua Y, et al. Attenuating PI3K/Akt- mTOR pathway reduces dihydrosphingosine 1 phosphate mediated collagen synthesis and hypertrophy in primary cardiac cells[J]. Int J Biochem Cell Biol, 2021,134:105952. doi:10.1016/j.biocel.2021.105952.
[15] 贺洵莹,杜雄兵.血浆1-磷酸神经鞘氨醇和鞘磷脂在缺血性心肌病收缩性心力衰竭的预测价值[J].广东医学,2018,39:3487-3490.doi:10.13820/j.cnki.gdyx.20181221.011.
[16] Mihanfar A, Nejabati HR, Fattahi A, et al. The role of sphingosine 1 phosphate in coronary artery disease and ischemia reperfusion injury[J]. J Cell Physiol, 2019,234:2083-2094. doi:10.1002/jcp.27353.
[17] Wu X, Reboll MR, Korf-Klingebiel M, et al. Angiogen-esis after acute myocardial infarction[J]. Cardiovasc Res, 2021,117:1257-1273. doi:10.1093/cvr/cvaa287.
[18] Polzin A, Dannenberg L, Benkhoff M, et al. Sphingosine-1-phosphate improves outcome of no-reflow acute myocardial infarction via sphingosine-1-phosphate receptor 1[J]. ESC Heart Fail,2023,10:334-341. doi:10.1002/ehf2.14176.
[19] Fang R, Zhang LL, Zhang LZ, et al. Sphingosine 1-phosphate postconditioning protects against myocardial ischemia/reperfusion injury in rats via mitochondrial signaling and Akt-Gsk3β phosphorylation[J]. Arch Med Res,2017,48:147-155. doi:10.1016/j.arcmed.2017.03.013.
[20] Cong D, Yu Y, Meng Y, et al. Dexmedetomidine (Dex) exerts protective effects on rat neuronal cells injured by cerebral ischemia/reperfusion via regulating the Sphk1/S1P signaling pathway[J]. J Stroke Cerebrovasc Dis, 2023,32:106896. doi:10.1016/j.jstrokecerebrovasdis.2022.106896.
[21] Devarakonda T, Valle Raleigh J, Mauro AG, et al. Chronic treatment with serelaxin mitigates adverse remodeling in a murine model of ischemic heart failure and modulates bioactive sphingolipid signaling[J]. Sci Rep, 2022,12:8897. doi:10.1038/s41598-022-12930-x.

SphK/S1P在心血管疾病中的作用

Role of SphK/S1P in cardiovascular diseases

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	高源, 郑刚, 齐靖, 张凤. NLRP3炎性小体在心脏病发病中的作用研究进展[J]. 基础医学与临床, 2023, 43(7): 1162-1166.
[2]	杜丰禾, 刘暴. 血管周围脂肪组织炎性反应促进动脉粥样硬化作用机制的研究进展[J]. 基础医学与临床, 2023, 43(4): 685-689.
[3]	沈霞芬, 蔡强, 俞蔚, 许晓辉. 心血管疾病高危人群的影响因素及其关联分析[J]. 基础医学与临床, 2023, 43(11): 1655-1661.
[4]	马茜钰, 彭石, 张兆元, 张丹, 张锦. 盐皮质激素受体对心血管疾病影响的研究进展[J]. 基础医学与临床, 2022, 42(8): 1292-1296.
[5]	胡诗琪, 蓝彦琦, 吴寿岭, 王晓墨, 陈朔华, 汪国栋, 王丽. 肥胖及其变化对中国华北新发NAFLD成年男性患者心血管疾病发病风险的影响[J]. 基础医学与临床, 2022, 42(5): 788-794.
[6]	梁清, 陈丽红. 生物钟紊乱致心脏功能障碍的研究进展[J]. 基础医学与临床, 2022, 42(5): 799-803.
[7]	吴岳恒, 余细勇. 人工智能在心血管疾病研究和临床中的应用[J]. 基础医学与临床, 2022, 42(11): 1644-1649.
[8]	黄仙, 吴寿岭, 陈朔华, 孙园园, 张迪, 郭淑霞, 王丽. 全血铁和铜与心血管疾病关联的基于队列的病例对照研究[J]. 基础医学与临床, 2021, 41(5): 709-714.
[9]	袁玲, 聂卫, 王蕾, 王宏, 崔晓雪, 刘琳娜. 慢性肾脏病血管钙化大鼠并发心肌炎性反应[J]. 基础医学与临床, 2021, 41(2): 197-202.
[10]	时英, 郭永芳, 邓玉婷, 戴红艳, 管军. Salusin-β在心血管疾病中作用的研究进展[J]. 基础医学与临床, 2021, 41(2): 282-286.
[11]	冯冬萍, 商汉桥, 杨航, 张虎军, 张停, 杨梦溪, 屠强, 任景怡. 斑马鱼cetp基因敲除模型的建立及其肝脏转录组学分析[J]. 基础医学与临床, 2020, 40(7): 940-947.
[12]	宋绮蕊, 蔡军. 人工智能及机器学习在心血管疾病中的应用[J]. 基础医学与临床, 2020, 40(5): 707-710.
[13]	焦晓璐, 秦彦文. 血管紧张素转换酶2与心血管疾病研究进展[J]. 基础医学与临床, 2020, 40(5): 701-706.
[14]	张静, 王肖枭, 周怡, 王雪, 顾开明, 叶迎春. 肠道菌群与疾病相关性的研究进展[J]. 基础医学与临床, 2020, 40(2): 243-247.
[15]	朱坤, 戴日蕾, 朱文婷, 李贞燕, 曹春梅. 细胞焦亡与心血管疾病研究进展[J]. 基础医学与临床, 2020, 40(12): 1711-1715.